| Literature DB >> 30360475 |
Nurhisyam Zakaria1, Mohamad Azrul Mahdzir2, Mahfuzah Yusoff3, Norhafiza Mohd Arshad4, Khalijah Awang5,6, Noor Hasima Nagoor7,8.
Abstract
BACKGROUND: Pinnatane A from the bark of Walsura pinnata was investigated for its anti-cancer properties by analyzing the cytotoxic activities and cell cycle arrest mechanism induced in two different liver cancer cell lines.Entities:
Keywords: anti-cancer; apoptosis; cell cycle arrest; necrosis; triterpene
Mesh:
Substances:
Year: 2018 PMID: 30360475 PMCID: PMC6278294 DOI: 10.3390/molecules23112733
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structure of pinnatane A.
The effects of pinnatane A treatment for 24 h on various cell lines.
| Human Cell Lines | IC50 | SI a |
|---|---|---|
| Normal lung fibroblast (MRC-5) | 48.8 ± 1.0 | N.A. c |
| Breast adenocarcinoma (MCF-7) | 60.9 ± 2.3 | 0.80 |
| Breast adenocarcinoma (MDA-MB-231) | 92.9 ± 3.1 | 0.53 |
| Bladder carcinoma (EJ-28) | 33.9 ± 3.8 | 1.44 |
| Bladder carcinoma (RT-112) | 48.0 ± 4.6 | 1.02 |
| Cervical adenocarcinoma (HeLa S3) | 59.7 ± 0.9 | 0.82 |
| Cervical carcinoma (SiHa) | >100 b | N.C. d |
| Hepatocellular carcinoma (Hep3B) | 19.0 ± 0.5 | 2.57 |
| Hepatocellular carcinoma (HepG2) | 55.8 ± 2.3 | 0.87 |
| Lung adenocarcinoma (A549) | 50.9 ± 3.1 | 0.96 |
| Lung adenocarcinoma (SK-LU-1) | >100 b | N.C. d |
| Prostate carcinoma (DU 145) | 87.2 ± 2.1 | 0.56 |
| Prostate adenocarcinoma (PC-3) | 55.3 ± 3.9 | 0.88 |
a SI = IC50 value of normal cells/IC50 value of cancer cells; b denotes an overall cell viability level of > 50.00% after treatment with pinnatane A at 100.0 μM for 24 h; c N.A.: Not applicable; d N.C.: Not calculated because IC50 value was not determined.
The time-dependent effects of pinnatane A on liver cancer cell lines.
| Time (h) | MRC-5 | Hep3B | HepG2 | ||
|---|---|---|---|---|---|
| IC50 | IC50 | SI a | IC50 | SI a | |
| 12 | 86.0 ± 4.5 | 52.7 ± 5.5 | 1.63 | 70.7 ± 0.5 | 1.22 |
| 24 | 48.6 ± 1.2 | 19.0 ± 0.5 | 2.56 | 55.8 ± 2.3 | 0.87 |
| 48 | 53.3 ± 4.6 | 13.5 ± 1.6 | 3.95 | 17.1 ± 2.1 | 3.12 |
| 72 | 53.1 ± 0.8 | 5.0 ± 0.0 | 10.62 | 8.8 ± 0.6 | 6.03 |
a SI = IC50 value of normal cells/IC50 value of cancer cells.
Figure 2Pinnatane A induces cell death in Hep3B and HepG2 cell lines. A live/dead assay after treatment with pinnatane A and DMSO for 12 h. Green fluorescence denotes viable cells stained with calcein-AM, while reddish-orange fluorescence represents dead cells stained with ethidium homodimer. All results are expressed as a total percentage of viable cells from four random fields with mean ± standard deviation (SD) of three independent determinations. Scale bar represents 100 μm.
Figure 3Pinnatane A caused cell cycle arrest in Hep3B and HepG2 cell lines. (A) Cell cycle distribution of Hep3B and HepG2 cells with pinnatane A treatment for various time points (12, 24, and 48 h) using flow cytometry after staining with PI. (B) Hep3B and (C) HepG2 cells cell cycle phase distribution presented in four groups, which are the group I: sub-G0/G1 phase, group II: G0/G1 phase, group III: S phase, and group IV: G2/M phase. All results are expressed in the histogram as total percentages of cells from four different groups with mean ± SD of three independent determinations. All data collected from experiments were performed in three replicates and analyzed using the one-way analysis of variance (ANOVA) at a significance level of p < 0.05 and indicated by *.
Figure 4Pinnatane A induced apoptosis in Hep3B and necrosis in HepG2 cells. (A) Detection of apoptosis and necrosis using annexin V-FITC and PI dual staining on Hep3B and HepG2 cell lines treated with pinnatane A at 12, 24, and 48 h. (B) Hep3B and (C) HepG2 cell lines population were distributed as follows: I: non-stained cells indicating viable cells, II: annexin V-FITC stained indicating early apoptosis, III: annexin V-FITC and PI stained cells indicating late apoptosis or early necrosis, and IV: PI stained cells indicating late necrosis. All results are expressed in the histogram as total percentages of cells from four different quadrants with mean ± SD of three independent determinations. All data collected from experiments were performed in three replicates and analyzed using the one-way analysis of variance (ANOVA) at a significance level of p < 0.05 and indicated by *.
Figure 5Pinnatane A induced DNA laddering on Hep3B and smearing on HepG2 cells. A DNA fragmentation assay using agarose gel electrophoresis for Hep3B and HepG2 cells treated with pinnatane A at 12, 24, and 48 h. M: marker; UT: Untreated. P: Positive control Hep3B cells treated with cisplatin.